India will begin trials of two new drugs to treat Covid-19 as part of the WHO Solidarity Clinical Trials.

The WHO Solidarity PLUS experiment includes 52 nations, with India being one of them. The efficacy of another medicine, artesunate, which is used to treat severe malaria, is also being investigated by the Covid-19 research collaboration. This third medicine will be tested in several other nations.

This month, India will launch Solidarity PLUS, the next phase of the World Health Organization’s Solidarity trial, which will assess the efficacy of new medications in treating hospitalised patients with Covid-19.

Imatinib and Infliximab, two medications already in use for different illnesses, will be studied in the Indian trial. Imatinib is a drug that is used to treat cancer.

“The trials would most likely start as soon as we receive the medications,” a senior official said, adding that it probably be this month.

Medically Speaking Team

Recent Posts

India’s Digital Disease Surveillance: A Global Model

India has significantly strengthened its public health infrastructure through a robust digital disease surveillance system.…

3 mins ago

Study Reveals: This Diet May Increase the Risk of Lung Cancer

In recent years, diet and lifestyle have been recognized as crucial factors influencing cancer risk.…

23 hours ago

The Future of Surgery: Will Robots Replace Surgeons?

Surgical advancements have evolved significantly over the decades, leading to improved precision, reduced recovery time,…

23 hours ago

Delhi Woman’s Death Sparks Medical Negligence Row

A tragic incident in northwest Delhi has sparked a medical negligence controversy after a 20-year-old…

24 hours ago

ASHA Nirogi Maharashtra: Empowering Health Workers with Digital Training

Maharashtra is set to witness a significant transformation in its public health sector with the…

24 hours ago

Breathing Trouble at Night? It Could Be Sleep Apnea

Sleep is essential for overall health, yet many people suffer from sleep disorders that disrupt…

24 hours ago